These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Kidney function after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. Hansen HP; Nielsen FS; Rossing P; Jacobsen P; Jensen BR; Parving HH Kidney Int Suppl; 1997 Dec; 63():S49-53. PubMed ID: 9407421 [TBL] [Abstract][Full Text] [Related]
3. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Rossing P; Tarnow L; Boelskifte S; Jensen BR; Nielsen FS; Parving HH Diabetes; 1997 Mar; 46(3):481-7. PubMed ID: 9032106 [TBL] [Abstract][Full Text] [Related]
4. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Parving HH; Hommel E; Jensen BR; Hansen HP Kidney Int; 2001 Jul; 60(1):228-34. PubMed ID: 11422755 [TBL] [Abstract][Full Text] [Related]
5. Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years' experience. Parving HH; Rossing P; Hommel E; Smidt UM Am J Kidney Dis; 1995 Jul; 26(1):99-107. PubMed ID: 7611276 [TBL] [Abstract][Full Text] [Related]
6. Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. Tarnow L; Rossing P; Jensen C; Hansen BV; Parving HH Diabetes Care; 2000 Dec; 23(12):1725-30. PubMed ID: 11128341 [TBL] [Abstract][Full Text] [Related]
7. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. Parving HH; Jacobsen P; Tarnow L; Rossing P; Lecerf L; Poirier O; Cambien F BMJ; 1996 Sep; 313(7057):591-4. PubMed ID: 8806248 [TBL] [Abstract][Full Text] [Related]
8. Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. Hovind P; Rossing P; Tarnow L; Smidt UM; Parving HH Kidney Int; 2001 Jul; 60(1):277-83. PubMed ID: 11422762 [TBL] [Abstract][Full Text] [Related]
9. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. Jacobsen P; Andersen S; Jensen BR; Parving HH J Am Soc Nephrol; 2003 Apr; 14(4):992-9. PubMed ID: 12660333 [TBL] [Abstract][Full Text] [Related]
10. Low-protein diet and kidney function in insulin-dependent diabetic patients with diabetic nephropathy. Hansen HP; Christensen PK; Tauber-Lassen E; Klausen A; Jensen BR; Parving HH Kidney Int; 1999 Feb; 55(2):621-8. PubMed ID: 9987086 [TBL] [Abstract][Full Text] [Related]
11. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Jacobsen P; Andersen S; Rossing K; Jensen BR; Parving HH Kidney Int; 2003 May; 63(5):1874-80. PubMed ID: 12675866 [TBL] [Abstract][Full Text] [Related]
12. The effect of beta-blockade and angiotensin converting enzyme inhibition on kidney function in diabetic nephropathy. Hommel E J Hypertens Suppl; 1989 Sep; 7(7):S49-51. PubMed ID: 2575661 [TBL] [Abstract][Full Text] [Related]
13. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Nielsen FS; Rossing P; Gall MA; Skøtt P; Smidt UM; Parving HH Diabetes; 1997 Jul; 46(7):1182-8. PubMed ID: 9200654 [TBL] [Abstract][Full Text] [Related]
14. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Ruggenenti P; Perna A; Mosconi L; Pisoni R; Remuzzi G Kidney Int; 1998 May; 53(5):1209-16. PubMed ID: 9573535 [TBL] [Abstract][Full Text] [Related]
15. Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Parving HH; Smidt UM; Hommel E; Mathiesen ER; Rossing P; Nielsen F; Gall MA Am J Kidney Dis; 1993 Jul; 22(1):188-95. PubMed ID: 8322782 [TBL] [Abstract][Full Text] [Related]
16. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Rossing K; Christensen PK; Jensen BR; Parving HH Diabetes Care; 2002 Jan; 25(1):95-100. PubMed ID: 11772908 [TBL] [Abstract][Full Text] [Related]
17. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Laffel LM; McGill JB; Gans DJ Am J Med; 1995 Nov; 99(5):497-504. PubMed ID: 7485207 [TBL] [Abstract][Full Text] [Related]
18. Diabetic nephropathy and arterial hypertension. The effect of antihypertensive treatment. Parving HH; Andersen AR; Smidt UM; Christiansen JS; Oxenbøll B; Svendsen PA Diabetes; 1983 May; 32 Suppl 2():83-7. PubMed ID: 6400672 [TBL] [Abstract][Full Text] [Related]
19. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Jacobsen P; Andersen S; Rossing K; Hansen BV; Parving HH Nephrol Dial Transplant; 2002 Jun; 17(6):1019-24. PubMed ID: 12032191 [TBL] [Abstract][Full Text] [Related]
20. Micro-albuminuria and the organ-damage concept in antihypertensive therapy for patients with insulin-dependent diabetes mellitus. Mogensen CE; Petersen MM; Hansen KW; Christensen CK J Hypertens Suppl; 1992 Apr; 10(1):S43-51. PubMed ID: 1619502 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]